coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Smash PCN, Cheshire East (LAD) · Health Inequalities Profile

    PCN U25799 · NHS Cheshire and Merseyside Integrated Care Board · 7 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    74,776

    Registered population

    57.4% aged 18–64

    23.9%

    Aged 65+

    ICB 19.0% · England 17.9%

    3.4%

    Ethnic minority (non-White)

    1.3% Asian · England 9.6%

    4.4%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~3,117

    Core20 residents (est.)

    Resident basis; registered basis ~3,318 · see page 3

    13,630

    Hypertension register

    +5.23% in 3 yrs · England +5.60%

    678

    SMI register

    17.1% of Cheshire East (LAD)'s

    1,412

    COPD register

    Reviews -3.42% in 3 yrs

    Forecast to 2030

    15,897

    Hypertension patients, 2030

    +2,267 on today

    58.6%

    QRISK ≥20% on statins, 2030

    +1.13pp over 3 yrs

    5.9%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    61.0%
    Asthma annual reviews trail comparators.

    Annual asthma reviews reach 61.0% (Cheshire East (LAD) 64.5%, ICB 62.3%, England 65.7%), leaving an estimated 1,993 of 5,115 registered patients unreviewed.

    56.3%
    High-risk lipid therapy and SMI checks lag.

    Lipid-lowering therapy is 56.3% for QRISK ≥ 20% (England 63.6%) and 60.9% for CKD (England 70.3%), while SMI BP checks reach 77.1% (England 83.4%).

    74.6%
    Breast and cervical screening exceed benchmarks.

    Breast screening aged 53 to 70 is 74.6% (England 69.9%) after +11.3% three-year growth (England +8.4%), alongside 78.3% cervical screening aged 25-49 (England 66.8%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    With 23.9% aged 65+, the PCN serves an older population than national averages

    Across 74,776 registered patients, 23.9% (17,898) are aged 65+, above Cheshire East (22.6%), NHS Cheshire and Merseyside ICB (19.0%) and England (17.9%). Based on Census usual residents rather than registered patients, 96.6% identify as White (Cheshire East 94.4%, ICB 93.0%, England 81.1%), with an ethnic minority share of 3.4% (Asian 1.3%, Mixed 1.3%, Black 0.4%). Projected population growth to 2030 is 3.8% under unverified methodology (Cheshire East 3.4%, ICB 2.3%, England 2.3%). This older age demographic may concentrate chronic disease and frailty workload across the network's seven practices.

    Age profile

    0–1718.7%
    18–6457.4%
    65+23.9%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White96.6%
    Asian1.3%
    Mixed1.3%
    Black0.4%
    Other0.3%

    Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Cheshire East LA)2,1292,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)75.7%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.3%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Cheshire East LA)9391,0219552024/25
    Falls deaths, all ages, per 100,000 (Cheshire East LA)14.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Low overall deprivation conceals Core20 exposure spanning 10.2 pp across practices

    Overall deprivation is low, with an average IMD decile of 7.7 and 4.4% of registered patients in the Core20 cohort, compared with 9.2% in Cheshire East (LAD), 31.9% in the ICB, and 21.0% in England. Core20 exposure spans 10.2 pp across practices. Concentration is highest at Merepark Medical Centre (10.2%) and Oaklands (10.0%), whereas volume centres on Oaklands (1,180 estimated patients) and The Cedars Medical Centre (1,005 patients). Ashfields Primary Care Centre, Haslington Surgery, and Greenmoss Medical Centre record 0.0%.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Merepark10.2% · 755 patients
    Oaklands10.0% · 1,180 patients
    Cedars8.4% · 1,005 patients
    Waters Edge8.1% · 378 patients
    Ashfields Primary0.0% · 0 patients
    Haslington0.0% · 0 patients
    Greenmoss0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    678

    SMI register

    0.91% recorded prevalence

    299

    Learning disability register

    0.40% recorded prevalence

    18

    Care homes, 769 beds

    In the PCN catchment

    8.8%

    Provide unpaid care

    Cheshire East (LAD), Census 2021

    SMASH PCN records 678 severe mental illness patients (0.9%; Cheshire East 0.9%, NHS Cheshire and Merseyside ICB 1.1%, England 1.0%) and 299 with learning disabilities (0.4%; Cheshire East 0.5%, ICB 0.6%, England 0.6%), alongside 18 catchment care homes with 769 beds. Lower recorded prevalence may reflect coding or ascertainment variation rather than lower need, which clinical register audits would test.

    Severe mental illness: physical health checks

    SMI annual blood pressure checks reached 77.1% (Cheshire East (LAD) 79.0%, England 83.4%), falling 1.1 pp over three years (2023 to 2025; England +4.4 pp). Recorded BMI reached 82.6% (England 82.1%).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    13,630

    Hypertension register

    +5.23%

    Register growth, 3 yrs

    Cheshire East (LAD) +6.54% · England +5.60%

    −2.14pp

    BP control, under 80

    ≤140/90 · −1.67pp aged 80+

    +2,267

    More patients by 2030

    Forecast 15,897 (20.26%)

    Hypertension case-finding and control

    Hypertension recorded prevalence is 18.3% (13,630 patients), above Cheshire East (LAD) (17.3%), the ICB (16.8%) and England (15.2%). While 68.6% of patients aged under 80 achieve blood pressure control to <= 140/90 mmHg (England 67.8%), control fell 3.0% over three years (2023 to 2025; England +3.2%). Practice prevalence ranges from 15.4% at Waters Edge Medical Centre to 24.7% at Greenmoss Medical Centre.

    Lipids and statins

    At 56.3%, QRISK ≥ 20% lipid-lowering therapy trails Cheshire East (LAD) (61.2%), NHS Cheshire and Merseyside Integrated Care Board (63.2%) and England (63.6%), while CKD lipid therapy is 60.9% (England 70.3%).

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026130,902£1.80£1.71£1.86£235,624
    Cardiovascular (all), 2025201,218£4.14£4.37£3.33£833,043

    In 2026, 130,902 lipid-regulating drug items cost £1.80 each (Cheshire East (LAD) £1.72, NHS Cheshire and Merseyside Integrated Care Board £1.71, England £1.86), totalling £235,624. Spend was £7,854 less than at England's unit cost, but £11,781 more than at NHS Cheshire and Merseyside Integrated Care Board's unit cost.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −0.07%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.01%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 7.3% (5,115 patients; England 6.6%, Cheshire East (LAD) 6.9%), yet only 61.0% had an annual review (England 65.7%, Cheshire East (LAD) 64.5%), leaving an estimated 1,993 registered patients unreviewed. COPD prevalence is 1.9% (1,412 patients; England 1.9%), but 12-month reviews fell 3.4% over three years (2023 to 2025; England +2.8%) to 73.0% (England 76.4%). Prescribing for ages 5-19 is 1,483 items per 1,000 (England 1,488).

    Cancer register and children's immunisation

    Cancer register prevalence is 5.2% (3,841 patients; England 3.8%, Cheshire East (LAD) 4.9%). For childhood immunisations, MMR dose 1 at age 5 reaches 94.9% (England 91.7%), but MMR dose 2 drops 3.1 pp to 91.8% (England 82.8%), trailing the 95.0% target by 3.2 pp. Additionally, 4-in-1 booster coverage at age 5 is 89.8% (England 80.9%).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months94.8%

    England 91.0%

    6-in-1 complete primary course at 24 months94.3%

    England 92.2%

    MMR dose 1 at 24 months91.4%

    England 88.3%

    MMR dose 2 at age 591.8%

    England 82.8%

    4-in-1 pre-school booster at age 589.8%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    In 2022, across NHS Cheshire and Merseyside ICB, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%). Known-stage status was recorded for 72.8% of registered cancers (13,490 of 18,522; England 67.0%). Reaching the 75.0% national ambition would require about 2,640 extra early-stage diagnoses a year across the ICB. Meanwhile, SMASH PCN's cancer register grew +7.1% over three years (2023 to 2025), trailing Cheshire East (LAD) (+10.6%) and England (+9.0%). ICB stage data reflects wider system pathways rather than PCN performance; site-specific small numbers warrant caution, while trailing PCN register growth may reflect practice-level identification variations, unverified locally.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), Mid Cheshire Hospitals NHS Foundation Trust achieved 80.0% on the 28-day faster diagnosis standard, meeting the 75.0% target and exceeding the ICB (77.2%) and England (79.3%), while East Cheshire NHS Trust reached 81.1% and University Hospitals of North Midlands NHS Trust achieved 80.6%. On the 62-day referral to treatment standard, Mid Cheshire Hospitals achieved 71.1%, trailing the 85.0% standard and the ICB (76.2%) but in line with England (71.2%), ahead of East Cheshire NHS Trust (53.4%) and University Hospitals of North Midlands NHS Trust (68.8%). These provider metrics describe acute system performance rather than PCN delivery.

    Pathways within standard (%)Mid Cheshireof North MidlandsEast CheshireCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)79.9580.6581.0877.2579.32
    31-day treatment (96%)86.2193.8596.3095.7192.50
    62-day referral to treatment (85%)71.1268.8453.4176.2371.16
    Diagnostic waits over 6 weeks (%)Mid Cheshireof North MidlandsEast CheshireEngland
    MRI5.1536.1326.6221.40
    CT1.092.8611.499.92
    Echocardiography5.5145.3926.2428.48
    Colonoscopy30.3446.5310.8530.83
    Gastroscopy31.8915.4910.2529.02
    All 15 DM01 tests12.7222.9416.1723.14
    Community services activityCheshire East residentsCheshire and Merseyside ICB
    Care contacts72,825541,280
    Referrals18,28097,150
    Patients with a contact21,910146,240

    Community services (residents of Cheshire East), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 60.8% of community health service contacts among Cheshire East local authority residents (44,295 of 72,825 total contacts). Provider-level community data was not captured. These borough resident figures indicate heavy older-age community service reliance, though they cannot establish activity or reach for SMASH PCN registered patients.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Cedars1108.472.8%81.0%90.2%
    Ashfields Primary1490.066.4%82.0%86.6%
    Oaklands12010.070.7%63.2%85.0%
    Greenmoss1140.087.6%78.0%85.0%
    Merepark10510.256.1%78.4%80.6%
    Waters Edge1208.177.7%76.3%78.0%
    Haslington Surgery1030.071.2%87.4%72.2%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNCheshire East (LAD)AssetPCNCheshire East (LAD)
    Care homes (catchment)18 (769 beds)n/aSchools (catchment)69n/a
    Children's centres314Places of worship64272
    Libraries316Day centres (VCS)n/a1
    Children and young people (VCS)n/a1Carers support groups (VCS)n/a1
    Primary schools (LA maintained)841Primary academies1978
    Special schools25

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review recall

    Asthma annual review coverage is 61.0% (Cheshire East (LAD) 64.5%, ICB 62.3%, England 65.7%, denominator includes PCAs), leaving 1,993 of 5,115 registered patients unreviewed. For discussion: practices could run structured single-template recall and flexible review slots alongside inhaler prescribing checks, starting in higher-Core20 practices. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    High-risk lipid and BP escalation

    QRISK ≥ 20% lipid therapy is 56.3% (Cheshire East (LAD) 61.2%, ICB 63.2%, England 63.6%) and CKD lipid therapy is 60.9% (England 70.3%), while <80 BP control 3-year change is -3.0%. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Combined SMI physical health checks

    On the 678-patient SMI register (0.9% prevalence), 12-month BP checks are 77.1% (Cheshire East (LAD) 79.0%, ICB 81.3%, England 83.4%, incl. PCAs) after falling 1.1 pp over 3 years. Moderate effort to run.

    Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.

    Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Learning disability register review (p2)Learning disability: QOF prevalence75% annual health checks (Network Contract DES) · Oliver McGowanPCN
    Targeted Core20 practice outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI blood pressure recall (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Cardiovascular review and titration audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school MMR catch-up (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cancer register recording review (p7)Cancer: QOF prevalenceCore20PLUS5, 75% stage 1–2 by 2028PCN
    Option 1 · Structured asthma review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · High-risk lipid and BP escalation (p12)Hypertension register · Hypertension: QOF prevalence · Patients with QRISK ≥ 20% treated with lipid lowering therapyCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Combined SMI physical health checks (p12)Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15